HCPCS | Generic Name | Brand Name (Ascending) | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | Aprepitant | Emend | 125 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2003 | In Use | |||
NA | Aprepitant | Emend | 80 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2003 | In Use | |||
NA | Aprepitant | Emend | 40 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2003 | In Use | |||
J8501 | Aprepitant | Emend | 5 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Yes | 2003 | Jan. 1, 2005 | In Use | ||
J1453 | Fosaprepitant | Emend | 150 mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | No | 2008 | Jan. 1, 2009 | In Use | ||
C9477 | Elotuzumab | Empliciti | 1 mg | Immunotherapy | Monoclonal Antibody | SLAMF7 | No | 2015 | July 1, 2016 | Dec. 31, 2016 | No Longer Used | |
J9176 | Elotuzumab | Empliciti | 1 mg | Immunotherapy | Monoclonal Antibody | SLAMF7 | No | 2015 | Jan. 1, 2017 | In Use | ||
J9358 | Fam-trastuzumab deruxtecan-nxki | Enhertu | 1mg | Immunotherapy | Drug Antibody Conjugate | HER2, topoisomerase, tetrapeptide | No | 2019 | July 1, 2020 | In Use | ||
J9178 | Epirubicin | Epirubicin | 2 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1999 | Jan. 1, 2004 | In Use | ||
J9180 | Epirubicin | Epirubicin | 50 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1999 | Jan. 1, 2001 | Dec. 31, 2003 | No Longer Used | |
J0885 | Epoetin Alfa | Epogen, Procrit | 1000 units | Ancillary Therapy | Erythropoiesis-Stimulating Agent | No | 1989 | Jan. 1, 2006 | In Use | |||
C9215 | Cetuximab | Erbitux | 10 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2004 | Feb. 12, 2004 | Dec. 31, 2004 | No Longer Used | |
J9055 | Cetuximab | Erbitux | 10 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2004 | Jan. 1, 2005 | In Use | ||
S0177 | Levamisole | Ergamisol | 50 mg | Immunotherapy | Antiinfective Agent | antihelminitic | Yes | 1990 | 2000 | Jan. 1, 2002 | In Use | |
NA | Vorinostat | Erivedge | 100 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2006 | In Use | |||
NA | Apalutamide | Erleada | 60mg | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Yes | 2018 | In Use | |||
J9020 | Asparaginase | Erwinaze | 10, 000 units (I.U.) | Chemotherapy | Miscellaneous Agent | Enzyme | No | 1994 | Jan. 1, 1984 | In Use | ||
C9289 | Asparaginase | Erwinaze | 1,000 units (I.U.) | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2011 | April 4, 2012 | Dec. 31, 2014 | No Longer Used | |
J9019 | Asparaginase | Erwinaze | 10, 000 units (I.U.) | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2011 | Jan. 1, 2013 | In Use | ||
NA | Estradiol | Estrace | 0.5mg | Hormonal Therapy | Estrogen | Yes | 1998 | In Use | ||||
NA | Estradiol | Estrace | 1 mg | Hormonal Therapy | Estrogen | Yes | 1998 | In Use | ||||
NA | Estradiol | Estrace | 2 mg | Hormonal Therapy | Estrogen | Yes | 1998 | In Use | ||||
NA | Polyestradiol Phosphate | Estradurin, Estradurine | 40 mg | Hormonal Therapy | Estrogen Derivative | No | 1957 | Aug. 8, 2003 | No Longer Used | |||
J0207 | Amifostine | Ethyol | 500 mg | Ancillary Therapy | Chemoprotective | Detoxifying Agent | No | 1995 | Jan. 1, 1998 | In Use | ||
NA | Flutamide | Euflex, Eulexin | 125 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Yes | 1989 | In Use |
Found 669 results in 1 millisecond — Export these results
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.